The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
ConditionIgA Nephropathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorRuijin Hospital
About this trial
1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis. 3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation. 4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
No age limit, no gender limit;
Kidney biopsy confirmed primary IgA nephropathy;
Sign the informed consent form voluntarily
Disqualifiers
IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura;
IgAN is clinically diagnosed but not confirmed by pathology;
The patient refuses to participate;
Patients judged by other investigators to be unsuitable for inclusion in the study.
Trial population
Biopsy-proven primary IgAN patients
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The proportion of a decline in estimated glomerular filtration rate by > 50% from baseline
To evaluate the renal function
Time frame
1 year2
The proportion of doubling serum creatinine compared with baseline
To evaluate the renal function
Time frame
1 year3
Incidence of ESRD
To evaluate the renal function
Time frame
1 yearSecondary outcomes
1
Incidence of cardiovascular events
Record of Cardiovascular events during follow-up period
Time frame
1 year2
Incidence of All-cause death
Record of All-cause death during follow-up period
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Ruijin Hospital
Lead sponsor
RenJi Hospital
Collaborator
Huashan Hospital
Collaborator
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Collaborator
Source ClinicalTrials.gov